Hope for african kids with sickle cell: major hydroxyurea trial underway
NCT ID NCT06171217
First seen Apr 23, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests the safety and effectiveness of hydroxyurea, a medicine that helps manage sickle cell disease, in 811 children aged 3 to 10 in Africa. The goal is to see if the drug can reduce complications and make it more widely available. Participants take hydroxyurea long-term to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
-
Hospital Pediátrico David Bernardino
Luanda, Angola
-
KEMRI/Wellcome Trust Research
Kilifi, Kenya
-
Mbale Regional Hospital
Mbale, Uganda
Conditions
Explore the condition pages connected to this study.